A Study of Glumetinib in Combination With Osimertinib as 1st Line Treatment in Patients With Non-Small Cell Lung Cancer
A Multicenter, Randomized, Controlled Phase Ⅲ Clinical Study on the Efficacy and Safety of Glumetinib in Combination With Osimertinib as First-Line Treatment in Patients With Non-Small Cell Lung Cancer With Classic EGFR Mutations and MET Overexpression or Amplification
To evaluate the efficacy and safety of Glumetinib plus Osimertinib in patients with non-small cell lung cancer with classic EGFR mutations and MET overexpression or amplification.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Clinical Trials Information Group officer
- Número de teléfono: 031169085587
- Correo electrónico: ctr-contact@cspc.cn
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Able to understand and willingness to voluntarily provide written informed consent.
- Age 18 to 75 years, males or females.
- Patientsconfirmed unresectable locally advanced or metastatic NSCLC patients;.
- Ability to provide qualified tumor samples..
- Patients must harbor the 1 of the 2 common EGFR mutations clearly associated with EGFR-TKI sensitivity (i.e., 19Del and L858R) as well as MET overexpression and/or amplification. MET overexpression and amplification must be confirmed by the central laboratory.
- No prior systemic anticancer therapy (including chemotherapy, radiotherapy, biological therapy, immunotherapy, or any investigational drugs) for locally advanced or metastatic NSCLC, and the participant is not amenable to curative surgery or radiotherapy. For patients with recurrent disease following prior surgery, if prior adjuvant chemo/radiotherapy, neoadjuvant chemo/radiotherapy, or definitive chemoradiotherapy for advanced disease was received, disease progression should have occurred ≥ 6 months after the completion of the last treatment.
- Presence of at least one measurable lesion at baseline according to RECIST v1.1. The target lesion must not have received prior irradiation, or if previously irradiated, must show documented evidence of disease progression after radiotherapy. Brain metastases cannot be selected as target lesions.
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.
- Life expectancy ≥ 3 months.
- Adequate bone marrow reserve or organ function..
- Women of childbearing potential must use highly effective contraception. Women of childbearing potential must have a negative blood pregnancy test within 7 days before the first dose. Any male or female participant of childbearing potential must agree to use highly effective contraception throughout the study period and for 6 months after the last dose.
Exclusion Criteria:
- Prior treatment with any EGFR inhibitor or MET inhibitor.
- Concomitant driver alterations such as ALK, ROS1, RAS, BRAF, RET, and HER2 for which approved targeted therapies are clinically available, if the Investigator judges that the patients cannot benefit from this trial due to the concomitant alteration; or other alterations (e.g., those with substantial clinical evidence supporting a better intervention for the mutation) that, in the Investigator's judgment, preclude benefit from this trial..
- Prior antineoplastic therapy within 2 weeks prior to the first dose of study drug, including hormonal therapy, biologic therapy, immunotherapy (including but not limited to anti-PD-1/PD-L1 antibodies, anti-CTLA-4 antibodies, cellular immunotherapy, etc.), local infusion of antineoplastic agents, or Chinese herbal medicines and/or proprietary Chinese patent medicines with approved/intended indications for the treatment of lung cancer.
- Prior local radiotherapy (including radionuclide therapy such as strontium-89) within 2 weeks before the first dose of study drug; or, within 4 weeks before randomization, received bone marrow irradiation exceeding 30% or extensive-field radiotherapy..
- Clinically uncontrolled (requiring paracentesis or drainage) malignant pleural effusion, ascites, or pericardial effusion within 2 weeks prior to the first dose of study drug.
- Major surgical procedure or significant traumatic injury within 4 weeks prior to the first dose of study drug, or anticipated need for major surgery during the study period. Minor clinical procedures such as vascular access placement and core/needle biopsies are permitted.
- Presence of leptomeningeal carcinomatosis; presence of spinal cord compression; or symptomatic and unstable brain metastases, unless the participant has completed definitive treatment, has achieved neurological stability for at least 2 weeks prior to randomization, and requires no corticosteroids or anticonvulsants. Asymptomatic patients with brain metastases (e.g., without neurological deficits, seizures, or other typical signs/symptoms of central nervous system [CNS] metastasis) may be enrolled if the investigator assesses that there is no indication for immediate definitive intervention.
- Use of strong CYP3A4 inducers within 2 weeks prior to the first dose of study drug, or inability to discontinue strong CYP3A4 inducers during the study period.
- History of autoimmune diseases, immunodeficiency disorders (including positive HIV serology), other acquired or congenital immunodeficiency diseases, or history of solid organ or bone marrow transplantation.
- Active infection (e.g., the participant is receiving anti-infective therapy).
- Severe or uncontrolled cardiovascular diseases requiring medical treatment.
- History of hypersensitivity to the active or inactive excipients of osimertinib, gumarontinib/placebo, or chemotherapy agents (pemetrexed and cisplatin/carboplatin), or to drugs of similar chemical structure or class; contraindications to chemotherapy agents (pemetrexed and cisplatin/carboplatin).
- Failure to adequately recover from toxicities and/or complications resulting from any prior interventions prior to treatment initiation (i.e., not recovered to Grade ≤ 1, excluding fatigue or alopecia).
- Current diagnosis of other malignancies or a history of other active malignancies within 5 years prior to the first study treatment, with the exception of clinically cured localized neoplasms (e.g., basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder carcinoma, prostate carcinoma in situ, cervical carcinoma in situ, breast carcinoma in situ, or papillary thyroid carcinoma).
- Definite prior history of neurological or psychiatric disorders, including epilepsy or dementia.
- Pregnant or lactating women.
- Participation in another investigational drug clinical trial and receipt of investigational drug within 3 weeks prior to the first dose of study drug.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Arm A
Glumetinib 300 mg orally once daily (QD) + Osimertinib 80 mg orally QD,every 3 weeks |
Glumetinib 300 mg QD orally under fasting conditions Administered orally at a dose of 80 mg QD orally |
|
Comparador de placebos: Arm B
Placebo 300 mg orally QD + Osimertinib 80 mg orallyQD,every 3 weeks |
Administered orally at a dose of 80 mg QD orally Placebo 300 mg QD orally under fasting conditions |
|
Comparador activo: Arm C
Osimertinib 80 mg QD and platinum-based chemotherapy Osimertinib 80 mg in combination with pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks. |
Administered orally at a dose of 80 mg QD orally Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks. Pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
FS as assessed by IRC
Periodo de tiempo: Up to approximately 42 months after the first patient is enrolled
|
Progression-free survival (PFS) using IRC as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) |
Up to approximately 42 months after the first patient is enrolled
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
ORR as assessed by IRC
Periodo de tiempo: Up to approximately 42 months after the first patient is enrolled
|
Objective response rate (ORR) as assessed by IRC |
Up to approximately 42 months after the first patient is enrolled
|
|
DCR as assessed by IRC
Periodo de tiempo: Up to approximately 42 months after the first patient is enrolled
|
Disease control rate (DCR) as assessed by IRC |
Up to approximately 42 months after the first patient is enrolled
|
|
DOR as assessed by IRC
Periodo de tiempo: Up to approximately 42 months after the first patient is enrolled
|
Duration of Response (DOR) as assessed by IRC |
Up to approximately 42 months after the first patient is enrolled
|
|
TTR as assessed by IRC
Periodo de tiempo: Up to approximately 42 months after the first patient is enrolled
|
Time to Response (TTR) as assessed by IRC |
Up to approximately 42 months after the first patient is enrolled
|
|
PFS as assessed by Investigator
Periodo de tiempo: Up to approximately 42 months after the first patient is enrolled
|
PFS as assessed by Investigator |
Up to approximately 42 months after the first patient is enrolled
|
|
ORR as assessed by Investigator
Periodo de tiempo: Up to approximately 42 months after the first patient is enrolled
|
ORR as assessed by Investigator |
Up to approximately 42 months after the first patient is enrolled
|
|
DCR as assessed by Investigator
Periodo de tiempo: Up to approximately 42 months after the first patient is enrolled
|
DCR as assessed by Investigator |
Up to approximately 42 months after the first patient is enrolled
|
|
DOR as assessed by Investigator
Periodo de tiempo: Up to approximately 42 months after the first patient is enrolled
|
DOR as assessed by Investigator |
Up to approximately 42 months after the first patient is enrolled
|
|
TTR as assessed by Investigator
Periodo de tiempo: Up to approximately 42 months after the first patient is enrolled
|
TTR as assessed by Investigator |
Up to approximately 42 months after the first patient is enrolled
|
|
OS
Periodo de tiempo: Up to approximately 42 months after the first patient is enrolled
|
Overall Survival (OS) |
Up to approximately 42 months after the first patient is enrolled
|
|
Safety
Periodo de tiempo: Up to approximately 42 months after the first patient is enrolled
|
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs), the other safety variables including physical examination, vital signs and laboratory examinations. |
Up to approximately 42 months after the first patient is enrolled
|
|
PK parameters
Periodo de tiempo: Up to approximately 42 months after the first patient is enrolled
|
Plasma concentration of Glumetinib |
Up to approximately 42 months after the first patient is enrolled
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Neoplasias por sitio
- Neoplasias
- Enfermedades de las vías respiratorias
- Enfermedades pulmonares
- Neoplasias de las vías respiratorias
- Neoplasias torácicas
- Neoplasias Pulmonares
- Carcinoma Broncogénico
- Neoplasias Bronquiales
- Carcinoma de pulmón de células no pequeñas
- Aminoácidos, péptidos y proteínas
- Químicos orgánicos
- Compuestos heterocíclicos
- Compuestos heterocíclicos, 2 anillos
- Compuestos heterocíclicos, anillo fusionado
- Químicos inorgánicos
- Compuestos de cloro
- Compuestos de nitrógeno
- Complejos de coordinación
- Guanina
- Hipoxantino
- Purinones
- Purinas
- Glutamatos
- Aminoácidos, ácido
- Aminoácidos
- Aminoácidos, dicarboxílico
- Compuestos de platino
- Pemetrexed
- Carboplatino
- Cisplatino
- osimertinib
- glumetinib
Otros números de identificación del estudio
Otros números de identificación del estudio
- SYH2065-007
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .